Antibodies

13 Jan 2021 UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
12 Jan 2021 Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
12 Jan 2021 DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2, Lead Candidates Described in Science Publication
12 Jan 2021 Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
12 Jan 2021 AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development
12 Jan 2021 Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
11 Jan 2021 Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial
11 Jan 2021 ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
11 Jan 2021 Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
07 Jan 2021 Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
07 Jan 2021 REMD Biotherapeutics Completes Enrollment and Announces Top-line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 Diabetes
06 Jan 2021 Novel Treatment Pioneered by MSK Kids Researchers Receives FDA Approval for Patients with High-Risk Neuroblastoma
06 Jan 2021 Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones
06 Jan 2021 Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101 in NAFLD patients
06 Jan 2021 Y-Biologics signed License Agreement with 3D Medicines for T cell bispecific engager in Greater China territory
05 Jan 2021 Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
05 Jan 2021 Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
05 Jan 2021 F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
05 Jan 2021 Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer
05 Jan 2021 Innate’s First NK Cell Engager Selected by Sanofi as Drug Candidate for Development
05 Jan 2021 Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection
05 Jan 2021 Provention Bio Announces U.S. FDA Filing of a Biologics License Application (BLA) and Priority Review for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals
05 Jan 2021 European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) as Adjuvant Treatment for Resected Esophageal or Gastroesophageal Junction Cancer Following Chemoradiotherapy
05 Jan 2021 European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Combined with Chemotherapy as First-Line Treatment in Metastatic Gastric Cancer, Gastroesophageal Junction Cancer and Esophageal Adenocarcinoma
05 Jan 2021 Genentech’s Novel Anti-TIGIT Tiragolumab Granted FDA Breakthrough Therapy Designation in Combination With Tecentriq for PD-L1-High Non-Small Cell Lung Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top